Stocktoria
CASTLE BIOSCIENCES INC CSTL
CASTLE BIOSCIENCES INC (CSTL) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $344.2M at a -7.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.505 |
| Retained earnings / assets | -0.388 |
| EBIT / assets | -0.074 |
| Equity / liabilities | 4.373 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CSTL | CASTLE BIOSCIENCES INC | 3/9 | 6.15 | — | +3.7% |
| FLGT | Fulgent Genetics, Inc. | 3/9 | 14.37 | — | +13.8% |
| CDNA | CareDx, Inc. | 4/9 | 0.16 | — | +13.8% |
| BLLN | BillionToOne, Inc. | 7/9 | 7.37 | 729.2 | +100% |
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
| GRAL | GRAIL, Inc. | 4/9 | -2.86 | — | +17.2% |
| BDSX | BIODESIX INC | 3/9 | -19.59 | — | +24.1% |
About CASTLE BIOSCIENCES INC
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
FAQ
Is CSTL financially healthy?
CASTLE BIOSCIENCES INC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CSTL pay a dividend?
No, CASTLE BIOSCIENCES INC does not currently pay a dividend.
How profitable is CSTL?
In FY2025, CASTLE BIOSCIENCES INC had a net margin of -7.0% and a return on equity of -5.1%.
What is the analyst price target for CSTL?
The average Wall-Street price target for CASTLE BIOSCIENCES INC is $43.56, about 38.6% above the recent price, from 9 analysts (consensus: strong buy).
Is CSTL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CASTLE BIOSCIENCES INC: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.